The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Headline
The AHA May 27 filed an amicus brief in the 7th U.S. Circuit Court of Appeals supporting the dismissal of an online tracking lawsuit against a member hospital…
Headline
Daniel Daly, Ph.D., executive director of the Center for Theology and Ethics in Catholic Health at the Catholic Health Association, explores the ethical future…
Headline
The Food and Drug Administration has issued an early alert for all heart pump controllers by Abiomed, which sent a correction notice to all customers with…
Headline
The AHA wrapped up its inaugural Healthier Together Conference in Dallas May 14 with a plenary session on how the application of artificial intelligence-driven…
Headline
The Medicaid and CHIP Payment and Access Commission approved recommendations it will issue to Congress in its June report on oversight and increased…
Headline
John Riggi, AHA national advisor for cybersecurity and risk, will moderate a webinar May 5 at 1 p.m. ET that will explore how bad actors are leveraging…